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1. Introduction 
Lipoproteins are complex aggregates of lipids and proteins that render endogenous lipids 
compatible with the aqueous environment of body fluids (Brown, 2007). The major 
physiological role of lipoproteins is to transport water-insoluble lipids from their point of 
origin to their respective destinations. Lipoproteins are synthesised mainly in the liver and 
intestines. They are in a state of constant flux, in circulation, changing in composition and 
physical structure as the peripheral tissues take up the various components before the 
remnants are returned to the liver. The most abundant lipid constituents of lipoproteins are 
free cholesterol, cholesterol esters, triacylglycerols and phospholipids, though fat-soluble 
vitamins and anti-oxidants are also found in lipoproteins (Kwiterovich, 2000). 
Classification of lipoproteins 
Lipoproteins are classified as chylomicrons (CM), very-low-density lipoproteins (VLDL), 
low-density lipoproteins (LDL) and high-density lipoproteins (HDL), based on the relative 
densities of the aggregates on ultracentrifugation. These classes are further refined by 
improved separation procedures, and intermediate-density lipoproteins (IDL) and 
subdivisions of the HDL (e.g. HDL1, HDL2, HDL3 etc) are often defined. Density of 
lipoproteins is determined largely by the relative concentrations of triacylglycerols and 
proteins and by the diameters of the broadly spherical particles, which vary from about 
6000Å in CM to 100Å or less in the smallest HDL. An alternative nomenclature is based on 
the relative mobilities on electrophoresis on agarose gels. Thus, α, pre-β and β lipoproteins 
correspond to HDL, VLDL and LDL, respectively (Lacko et al., 2007). 
Chylomicrons  
Chylomicrons, the largest and least dense of the lipoproteins are formed in the intestinal cell 
walls from dietary fat and cholesterol. Their main task is to carry triglycerides from the 
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intestine to the tissues where they are needed as a source of energy. In the circulation, 
triglycerides are removed from chylomicrons via the action of lipoprotein lipase (LPL), an 
enzyme present in the capillaries of many tissues. If present in large amounts, such as after a 
fatty meal, chylomicrons cause the plasma to appear milky. 
Very low density lipoproteins  
Very low density lipoproteins (VLDLs) are synthesised in the liver. Much like chylomicrons, 
they function primarily to distribute triglycerides to target sites such as adipose tissue and 
skeletal muscle where they are used for storage and energy. The manner in which 
triglycerides are removed from the circulation is the same as that of chylomicrons. 
Gradually with removal of triglycerides and protein, VLDLs are converted to LDL. High 
plasma levels of VLDL are associated with familial hypertriglyceridaemia, diabetes mellitus 
and underactive thyroid. 
Low density lipoproteins 
Low density lipoproteins are cholesterol-rich particles. About 70% of plasma cholesterol 
occurs in this form. LDLs are chiefly involved in the transport of the cholesterol 
manufactured in the liver to the tissues, where it is used. Uptake of cholesterol into cells 
occurs when lipoprotein binds to LDL receptors on the cell surface. LDL is then taken into 
the cell and broken down into free cholesterol and amino acids. Disorders involving a defect 
in or lack of LDL receptors are usually characterised by high plasma cholesterol levels. The 
cholesterol cannot be cleared efficiently from the blood and therefore accumulates.  
High density lipoproteins 
The high-density lipoproteins (HDLs) are small, dense, and spherical lipid-protein complexes 
which are normally considered to consist of those plasma lipoprotein particles which fall into 
the density range of 1.063–1.210 g/mL. HDL particles are composed of an outer layer 
containing free cholesterol, phospholipid, and various apolipoproteins (Apo), which covers a 
hydrophobic core consisting primarily of triglycerides and cholesterol esters (Barter et al., 
2003). The major proteins are Apo A-I (Mr 28,000) and Apo A-II (Mr 17,000). Apo A-I, the 
primary protein constituent of these particles, accounts for about 60% of the protein content of 
HDL. Apo A-I is synthesized in the intestines and liver and is thought to be largely responsible 
for the antiatherogenic effects of HDL. Some HDL particles carry only Apo A-I, whereas others 
contain both Apo A-I and Apo A-II (Shah et al., 2001). Other apolipoprotein species found in 
HDL particles include Apo A-IV, Apo C (C-I, C-II, and C-III), and Apo E. 
High density lipoprotein subtypes  
Several subtypes of HDL particles have been identified on the basis of density, 
electrophoretic mobility, particle size, and apolipoprotein composition (Albers et al., 1984). 
Differences in particle size are mainly the result of the number of apolipoprotein particles 
and the volume of the cholesterol ester in the core of the particle. HDL can also be classified 
into larger, less dense HDL2 or smaller, denser HDL3 which falls within the density ranges 
1.063–1.125 and 1.125–1.210 g/mL, respectively. Although the major proportion of HDL is 
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normally present in HDL3, individual variability in HDL levels in human populations 
usually reflects different amounts of HDL2 (Skinner, 1994). HDL2 is richer in particles 
containing Apo A-I without Apo A-II, whereas HDL3 is richer in particles containing both 
Apo A-I and Apo A-II (Gotto, 2001). 
Synthesis, Metabolism and Regulation of plasma lipoprotein concentration 
Normal metabolism and homeostasis of carbohydrates, amino acids and lipids in vivo 
depend on integrated liver function. Most plasma apolipoproteins and endogenous lipids 
and lipoproteins, including apolipoprotein(a) (apo(a)) and lipoprotein(a) (Lp(a)), are 
synthesized in the liver. The apolipoprotein(a) is a high molecular weight glycoprotein, of  
250-838 kD (Bowden, 1994) and a total of 34 different apo(a) isoforms have been identified in 
populations (Marcovina et al., 1993). The core components of Lp(a) are neutral lipid and an 
apoB-100 molecule, which are covalently connected by a disulfide-bond bridge and 
surrounded by hydrophilic apo(a) (Byrne, 1994). The heterogeneity of apo(a) determines the 
changes in plasma Lp(a) concentrations, and there is a negative correlation between the 
molecular weight of apo(a) and the plasma Lp(a) concentration (Wade, 1993) 
Lp(a) has a simple Mendelian dominant inheritance, which is controlled by the alleles Lpa 
and Lp0 (Utermann et al., 1988). Plasma Lp(a) concentration is controlled by three alleles., 
i.e., LpA, Lpa and Lp0 (Hasstedt et al. 1986). Pedigree analysis indicated that the size 
polymorphism of Lp(a) is controlled by a series of alleles of a single point (Utermann, 1988). 
The apo(a) gene which is located in q26-27 of chromosome 6 in humans has a linkage to the 
plasminogen (PGN) gene, and is inherited in a codominant Mendelian model (Amemiya, 
1996). Apolipoprotein(a) mRNA (14 kb) encodes for a mature protein of 4529 amino acid 
residues in the presence of a signal peptide with 19 amino acid residues (McLean, 1987) 
while a high-degree homology exists between the molecular structures of the apo(a) gene 
and the PGN gene. The high-degree homology between the apo(a) gene and the PGN gene 
determines the biological actions of Lp(a) (Romics et al., 1996).  
2. Role of lipoprotein in cancer 
Cancerous cells generally have high requirements for cholesterol as they are rapidly dividing 
cells. The Low density lipoproteins (LDL) which are cholesterol-rich particles have been 
especially found to play significant role in the pathogenesis of a large number of cancers. For 
instance, increased LDL requirement and receptor activity have been reported in cancer of the 
prostate gland (Chen and Hughes-Fulford, 2001); colon (Niendorf  et al., 1995); adrenal gland  
(Nakagawa et al., 1995); hormone unresponsive breast tumors (Stranzl et al., 1997), cancers of 
gynecological origin, tumors of lung tissues (Vitols et al., 1992), leukemia (Tatidis et al., 2002), 
and malignant brain tumors (Rudling et al., 1990). In contrast, high density lipoproteins (HDL) 
have been reported significantly lowered in patients with primary or metastatic liver cancer 
(Moorman et al., 1998). Hoyer and Engohm (1992) observed an inverse association between 
serum HDL-cholesterol and risk of breast cancer in a cohort of 5,207 Danish women, who 
participated in the Glostrup population studies of breast cancer. 
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Lymphoma patients often exhibit abnormal lipid metabolism. Numerous clinical studies of 
lymphoma patients have reported lipid abnormalities that are similar to the dyslipidemia 
observed in inflammatory and infectious diseases that are believed to develop secondary to 
circulating cytokines and the accompanying acute-phase response (Blackman et al., 1993). 
Spiegel et al. (1989) investigated plasma lipids and lipoproteins at presentations in 25 
patients with acute leukemia and non-Hodgkin's lymphoma and reported that all patients 
demonstrated an abnormality in at least one plasma lipid fraction and most exhibited a 
predictable pattern of lipid alterations that consisted of extremely low levels of HDL-
cholesterol, elevated triglyceride, and elevated very low density lipoprotein (VLDL). The 
degree of lipid abnormality was directly related to the underlying tumor burden and 
particularly to the presence of bone marrow involvement. Therefore, low levels of 
circulating HDL-cholesterol in lymphoma patients may occur before the clinical onset of 
cancer and may serve as a marker for inflammation-induced lymphomagenesis, rather than 
a consequence of lymphoma-induced acute-phase responses. 
2.1. Role of lipoprotein(a) in pathogenesis of cancer 
Lipoprotein[a] is an intriguing molecule consisting of a low-density lipoprotein core and a 
covalently bound apolipoprotein[a]. Apolipoprotein[a] possess an inactive protease domain 
which is a single copy of the plasminogen kringle 5 and multiple repeats of domains 
homologous to the plasminogen kringle 4. The plasminogen kringle 5 (K5) domain, which is 
distinct from angiostatin, possesses potent anti-angiogenic properties on its own, which can 
be exploited in cancer therapy. The angiostatic effect and novel proinflammatory role of the 
K5 protein is via its ability to recruit tumor-associated neutrophils and NKT lymphocytes, 
leading to a potent antitumor response (Perri et al., 2007).  
Recently, anti-angiogenic agents have been found to promote leucocyte-vessel wall 
interaction as part of their anti-tumorigenic effects. Studies on animal models have indicated 
that the proteolytic break-down products of apolipoprotein[a] may posses anti-angiogenic 
and anti-tumorigenic effects both in vitro and in vivo. This is a convenient premise to 
develop novel therapeutic modalities which may efficiently suppress tumor growth and 
metastasis (Giuseppe et al., 2007). Significant decrease in Lipoprotein[a] levels have been 
reported in liver cancer patients by Samonakis et al., 2004. Although the liver plays an 
important role in lipid metabolism, several non-hepatic factors such as hormones, cytokines, 
genetics and nutrition are also involved in different ways. For example, several 
inflammatory and tumoral diseases are characterized by the production and delivery of 
cytokines influencing serum Lipoprotein[a] levels.  
The mechanisms by which cancers induce cachexia involve inflammatory cytokine production; 
which is responsible for a wide number of metabolic disorders, essentially involving lipid 
metabolism (Langstein and Norton, 1991) and serum Lipoprotein[a] level changes during 
inflammatory disease.  Liver damage has been linked to reduce Lipoprotein[a] serum levels 
(Malaguarnera et al., 1996). Geiss et al.(1996) observed marked increase in Lipoprotein[a] 
concentration from 7 mg/dl in acute stage to 32 mg/dl in convalescence in hepatitis 
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patients.The lipoprotein[a] half-life is short in vivo, 3.3~3.9 d, (Krempler et al., 1983), and 
influenced early by liver function alterations (Malaguarnera et al., 1994), The high involvement 
of Lipoprotein[a] in lipid and protein metabolism have been suggested to be a sensitive and 
early marker of liver malfunction, therefore Lipoprotein[a] may supply useful additional 
information for a more complete assessment and monitoring of the liver function in patients 
with hepatocellular carcinoma and liver cirrhosis (Uccello et al., 2011). 
2.1.1. Role of high density lipoprotein (HDL) in the pathogenesis of cancer 
The origin and fate of HDL are less well understood than other lipoproteins. HDL may be 
formed both in the intestine and in the liver. It is also formed during lipolysis of 
Triglycerides-rich lipoproteins. Apolipoprotein AI (ApoAI) and apolipoprotein AII (apoAII) 
are the major apolipoproteins of HDL and the production rate of apoA-I is an important 
determinant of the variability of plasma HDL concentrations. Production rate of apoA-I is 
however, influenced by many factors and apoA-I transcriptional regulation has an impact 
on plasma HDL concentrations.  
A large number of cellular lipid transporters and receptors including a spectrum of HDL and 
intermediates of HDL participate in the transport of excess cholesterol from peripheral cells to 
the liver. At one end of the spectrum are lipid-free or lipid-poor apoA-I particles, referred to as 
pre-β HDL. These particles are secreted by the liver and small intestine or generated from 
surface material from partially lipolyzed chylomicrons  or from HDL2 in the periphery by the 
action of cholesteryl ester transfer protein (CETP), hepatic lipase, or phospholipid transfer 
protein (PTP) (Dullaart  et al., 2001). Lipolyzed chylomicrons are HDL precursors that accept 
unesterified cholesterol and phospholipids transferred by ATP-binding cassette transporter A1 
(ABCA1) on peripheral cells, giving rise to discoidal lipoproteins containing apoA-I (Yokoyama, 
2005). The acquired unesterified cholesterol of the apoA-I is esterified by the plasma enzyme 
lecithin:cholesterol acyltransferase (LCAT) to form cholesteryl ester which is packaged into the 
hydrophobic core of the discoidal particle, converting it to spherical HDL3. HDL3 can continue 
to accept unesterified cholesterol and phospholipids from the class B, type I scavenger receptor 
(SR-BI); through continued action of LCAT (Fig. 1). This causes the hydrophobic core of the 
discoidal lipoprotein particle to expand and the size increases, thereby forming HDL2.  
High density lipoprotein (HDL) plays a key role in the reverse cholesterol transport 
pathway (RCTP) (Genest et al., 1990) and various fractions of HDL have been shown to offer 
a new approach to study liver diseases (Cooper et al., 1996). Plasma HDL-C, HDL-PL and 
HDL-C/HDL-PL have been reported to be lower in hepatocellular carcinoma patients than 
those in normal patients (Li et al., 1993). In a study on 40 patients with hepatocellular 
carcinoma, LDL-C level was found to be significantly lower in the hepatocellular carcinoma 
patients than in the controls, but HDL-C did not show a statistically significant difference to 
the controls (Motta et al., 2001). HDL-C itself has also been reported significantly decreased 
in patients with primary or metastatic liver cancer (Kanel et al. 1983). Therefore, variations in 
the level of plasma lipids and lipoproteins may assist in describing the nature of cirrhosis 
and hepatocellular carcinoma (Ahaneku et al., 1992). 
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Figure 1. Formation of HDL2 from unesterified cholesterol  
Furthermore, an inverse and significant association exists between levels of HDL cholesterol 
and the risk of incident cancer, according to the results of a recent study (Jafri et al., 2010). 
Exceptionally, a few cancer risk factors are associated with increased levels of HDL. For 
instance, many breast cancer risk factors are associated with high HDL-C and the 
relationship between breast cancer and HDL-C is independent of other risk factors 
(Moorman et al., 1998). 
HDL could play a role in carcinogenesis through its influence on cell cycle entry, via a 
mitogen-activated protein kinase-dependent pathway or regulation of apoptosis. 
Specifically, an inverse association exists between serum HDL and risk of breast cancer, 
and several studies have reported lower levels of HDL in breast cancer patients. Further 
studies have also shown that tumor progression from localized to metastatic disease is 
associated with declining HDL levels. At least two population-based screening surveys 
involving Norwegian women have established low HDL, as part of the metabolic 
syndrome associated with increased post-menopausal breast cancer risk. The risk of post-
menopausal breast cancer among overweight and obese women in the highest serum 
HDL-cholesterol quartile was one-third the risk of women in the lowest serum HDL-
cholesterol quartile (Furberg et al., 2004).  
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2.2. Serum lipid profile and incidence of cancer 
Cancer patients often present altered serum lipid profile including changes of HDL level. 
Case-control studies of newly diagnosed lung cancer have shown that HDL levels are 
reduced in lung cancer cases. Patients with advanced nonresectable lung cancer also often 
have decreased serum HDL. Although the biological mechanisms that might link low 
plasma levels of HDL with cancer are not well understood, the HDL regulation of cell cycle 
entry through a mitogen activated protein kinase-dependent pathway and apoptosis, 
modulation of cytokine production, and antioxidative function (Perletti et al., 1996) has been 
suggested biologically plausible.  
The association between higher HDL and lower overall cancer incidence observed in the 
ATBC cohort is biologically plausible, as HDL has anti-inflammatory properties (Perletti et 
al., 1996). However, it is also plausible that this association reflects the effect of factors such 
as inflammation, which are associated with both HDL and risk of cancer.  
2.3. Effect of inflammation on HDL levels in the body 
Inflammation reduces HDL and likely increases risk of lung cancer (Mendez et al., 1991). 
Studies have shown that chronic inflammation is known to reduce both serum HDL-
cholesterol levels and its anti-inflammatory properties. The lipoprotein abnormalities seen 
in patients with inflammatory diseases are thought to develop secondary to circulating 
cytokines and the accompanying acute-phase response (Blackman et al., 1993). Low HDL-
cholesterol may therefore be a marker for the severity of systemic inflammation and 
inflammation-induced non-Hodgkin's lymphoma risk. Conversely, high HDL-cholesterol 
itself may be protective against non-Hodgkin’s lymphoma. High-density lipoprotein-
cholesterol seems to modulate inflammatory responses independent of non-HDL cholesterol 
levels by suppressing chemotactic activity of monocytes and lymphocytes and inhibiting 
cytokine-induced expression of endothelial cell adhesion molecules.  
2.4. Association between antioxidant enzymes and HDL 
There are a number of enzymes associated with HDL that have antioxidant properties, 
including paraoxonase, platelet-activating factor acetylhydrolase, and glutathione 
peroxidase. Paraoxonase-1 (PON1), the enzyme primarily responsible for HDL's antioxidant 
function, is closely bound to the HDL particle. PON1's enzymatic activity is highly regulated 
by environmental factors such as diet and physical activity, by certain drugs, and by genetic 
factors, especially certain genetic polymorphisms in the paraoxonase-1 gene, PON1. PON1 is 
synthesized in the mammalian liver and circulates in blood bound to HDL apolipoprotein 
(apo) A-1 and apo J. There are 2 other proteins in the same family as PON1 that probably 
also have antioxidant actions. These are PON2 and PON3. PON2 is ubiquitously expressed 
within cells, whereas PON3 exhibits a basal constitutive antioxidant activity and is 
essentially bound to HDL (Reddy et al., 2001; Ng et al., 2001). These enzymes have the ability 
to prevent the formation of proinflammatory oxidized phospholipids and to block the 
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activity of those already formed; however, these oxidized lipids negatively regulate the 
activities of the HDL-associated enzymes. During an acute-phase response in rabbits, mice, 
and humans, there seems to be an increase in the formation of these oxidized lipids that 
results in the inhibition of the HDL-associated enzymes and an association of acute-phase 
proteins with HDL that renders HDL pro-inflammatory rather than being anti-
inflammatory.  
2.5. Role of lipoproteins in cancer chemotherapy 
The efficacy of cancer chemotherapy is often limited by severe cytotoxic effects induced by 
anticancer drugs, on healthy and cancerous cells (Sehouli et al., 2002).  In addition, most of 
the available dosage forms perform with less than optimal efficiency because of poor 
solubility and limited accessibility to target tissues (Rosen and Abribat, 2005). Furthermore, 
it is difficult to eradicate cancer cells in vivo because they share the same biochemical 
machinery with normal cells.  
In spite of the overwhelmingly large number of anticancer drugs that have been developed, 
none is completely selective for cancer cells. Consequently, all anticancer drugs presently in 
use induce significant dose-limiting toxic side effects. For this reason, there has been 
increased emphasis on selective delivery of drugs to tumours in ways that bypass normal 
body tissues.  
2.5.1. Lipoproteins as special anticancer drug delivery agent 
The cytotoxic effects of cancer chemotherapeutic drugs on healthy organs can be 
significantly diminished by employing special drug delivery systems targeted specifically to 
cancer cells (Minko et al., 2004). Targeting is especially important in circumstances where a 
localized tumor is removed surgically, and chemotherapy is prescribed as a follow-up 
preventive against potential metastases (Dharap et al., 2005). Among the vehicles that can be 
used for special anticancer drug delivery are lipoproteins.  
Lipoproteins have been considered appropriate drug-delivery vehicles for anticancer drugs 
(Braschi et al., 1999), owing to their structural features, biocompatibility and targeting 
capability via receptor mediated mechanisms (Nikanjam et al., 2007). The basic structure of 
lipoproteins, which comprises of an outer protein–phospholipid shell with a lipophilic 
surface and an interior hydrophobic compartment, positions them as ideal transporters of 
hydrophobic drugs, including anticancer agents. Due to their biocompatible, lipoproteins 
have considerable advantages over the conventional carrier systems currently used in cancer 
chemotherapy in that they provide the opportunity for targeted delivery of the anticancer 
drug they carry through endocytosis by receptor mediated uptake or by selective uptake of 
core components (Pathania, et al., 2003).  
The main advantages of lipoprotein-based formulations are their biocompatible 
components, their relative stability in the blood circulation and their track record of having 
already been safely injected into human subjects (Bisoendial et al., 2002). In addition, 
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lipoprotein-based formulations have vast targeting potential via receptor-mediated 
mechanisms that are overexpressed in cancer cells compared with normal cells. It has been 
shown that anticancer drugs can be targeted to cancer cells that generally express a high 
level of lipoprotein receptors, by encapsulation into reconstituted high density lipoprotein 
nanoparticles which are similar to the endogenous lipoprotein particles responsible for 
shuttling of hydrophobic molecules to different parts of the body.  
Lipoprotein complexes are ideal for loading and targeted delivery of cancer therapeutic and 
diagnostic agents because they can mimic the shape and structure of endogenous 
lipoproteins, and as such, remain in circulation for an extended period of time, while largely 
evading the reticuloendothelial cells in the body’s defenses. The small size (less than 30 nm) 
of the low-density and high-density classes of lipoproteins allows them to maneuver deeply 
into tumors. Furthermore, lipoproteins can be targeted to their endogenous receptors, 
especially, when the receptors are implicated in cancer. Although the lipophilic character of 
certain pharmaceuticals may be a disadvantage during intravenous therapy, this can be 
advantageous in anticancer drug deliveries as the highly lipid compounds are ideally suited 
for incorporation into lipoproteins. Most of the ‘orphaned’ anticancer drugs that have failed 
primarily due to their poor water solubility can also be made to progress faster through 
development process by incorporating them into lipoproteins.  
2.5.2. Low density lipoprotein in cancer chemotherapy 
Low density lipoprotein (LDL) has been found to represent a suitable carrier for cytotoxic 
drugs that may target them to cancer (Kader and Pater, 2002). This is because the low-density 
lipoprotein receptor (LDLR) has been found to be over-expressed in numerous cancers. The 
upregulated levels of low-density receptor in these cancers are believed to provide the cancer 
cells with the necessary lipid substrates needed for active membrane synthesis. In fact, 
sequestration of plasma LDL cholesterol in cancers has been suggested to explain the low 
levels of circulating total and LDL cholesterol observed in patients with malignancies. These 
findings have led many researchers to investigate the possibility of exploiting LDL as a 
delivery vehicle for cancer diagnostics and therapeutics (Corbin and Zheng, 2007).  
The high requirement of LDL by cancer cells and thus the overexpression of LDL receptor 
can be utilized for developing a novel targeted drug delivery system. This can be achieved 
by targeting of the LDL particle and allowing the anticancer drugs to be transferred to the 
natural LDL inside of the body. LDL will function as a secondary carrier of anticancer 
molecules and deliver these molecules selectively to cancerous cells via elevated LDL 
receptors. This approach requires the anticancer molecules to have affinity for the LDL 
particle endogenously and to have certain special physicochemical properties.  
There are at least three different ways in which diagnostic or anticancer agents can be 
incorporated into LDL. The first of these is protein labeling in which the anticancer drug 
is covalently attached to the amino acid residues of apolipoprotein (apo) B-100 protein of 
LDL; the second is surface labeling which involves intercalation of the diagnostic or 
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anticancer agent into the phospholipid monolayer of LDL; the third is reconstitution core 
loading via substitution of anticancer agents into the lipid core of LDL. A large number of 
researchers have shown that various anticancer agents could be actively incorporated into 
LDL through intercalation or reconstitution methods. Moreover, these novel LDL–drug 
complexes were shown to be more efficacious against cancer cells than their conventional 
counterparts.  
Coupling of doxorubicin to human LDL to form a LDL-doxorubicin complex injected to 
mice resulted in greater accumulation of LDL-doxorubicin, in the liver, than free 
doxorubicin. In contrast, LDL- doxorubicin was less accumulated in heart than free 
doxorubicin. This suggests LDL could be used as carriers to conjugate anti-cancer drugs.  
2.5.3. Problems limiting the use of LDL as delivery vehicle 
Although a lot of studies have produced promising results, progress towards utilizing LDL 
as a delivery vehicle in the clinical setting has been impeded by the need to isolate LDL from 
fresh donor plasma. Relying on donor plasma to acquire LDL is problematic because LDL 
samples vary from batch to batch, methods for isolating LDL are lengthy and large 
quantities of LDL are difficult to attain. Furthermore, isolated LDL can only be stored for 
finite periods before aggregation and degradation processes compromise the integrity of the 
LDL sample. As a result of these limitations, attempts have been made to prepare synthetic 
LDL-like particles consisting of phospholipid/cholesterol ester microemulsions and apoB-
100 (the LDLR-binding component of LDL). Difficulties also plagued this endeavor owing to 
the size and complexity of the apoB-100 protein which is one of the largest monomeric 
proteins known consisting of over 4500 amino acids with a molecular weight of 550 kDa. 
Furthermore, apoB-100 is highly insoluble in aqueous solutions, making it difficult to work 
with. In addition, these problems are compounded still by the difficulties of having to 
isolate apoB-100 from donor plasma and other approaches to working with apoB-100 are 
therefore needed.  
2.5.4. High-density Lipoprotein in cancer chemotherapy 
The targeted delivery of anticancer agents via lipoprotein carriers is based on the concept 
that cancer cells have a higher expression of lipoprotein receptors (Lacko et al., 2002; Cao et 
al., 2004) due to their increased need for cholesterol to promote rapid proliferation. Clinical 
studies have shown that HDL cholesterol levels, like LDL levels, are lower in cancer 
patients, including those with haematological malignancies (Fiorenza et al., 2000). 
Unfortunately, the targeting of chemotherapeutic agents via HDL is daunting because 
overwhelming efforts are required for the isolation HDL from human plasma and a lot of 
biosafety concerns are attached with the injection of human-blood-derived products (Adams 
et al., 2003). Consequently, the focus of future studies is likely to be on 
synthetic/reconstituted lipoproteins with favourable drug-carrying capacity, and the 
exploitation of their potential for targeting tumour ce
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HDL transports cholesterol to liver cells, where they are recognized and taken up via 
specific receptors. Cholesteryl esters within HDL are selectively uptaken by hepatocytes via 
the scavenger receptor class B type I (SR-BI). An interesting feature of SR-BI is that the 
receptor selectively translocates HDL-cholesteryl esters from the lipoprotein particle to the 
cytosol of the liver parenchymal cells without a parallel uptake of the apolipoproteins and 
this property may allow for the delivery of its loaded drugs avoiding lysosomal degradation 
(Lou et al., 2005). The high affinity of cancer cells for HDL has made them useful as carriers 
for delivering anticancer drugs into hepatoma cells to treat HCC. Anti-cancer drug-HDL 
complexes work as efficient drug delivery vehicles due to the ability of cancer cells to 
acquire HDL core components  (Wasan et al., 1996). Complexing of anti-cancer drugs with 
HDL does not influence characteristics of the anticancer drugs (Kader et al., 2002) and 
administration of anti-cancer drug-HDL complex may reduce toxic side-effects during the 
chemotherapy( Lacko, et al.,2002).  
In a cell culture system, cellular uptake of recombinant HDL-aclacinomycin by the 
SMMC-7721 hepatoma cells was significantly higher than that of free aclacinomycin at the 
concentration range of 0.5–10 μg/mL. Cytotoxicity of recombinant HDL- aclacinomycin to 
the hepatoma cells was significantly higher than that of free aclacinomycin at 
concentration range of less than 5 μg/mL just as IC50 of recombinant HDL-aclacinomycin 
was lower than IC50 of free aclacinomycin (Lou et al., 2005). These results strongly 
suggest that HDL could be used as carriers to conjugate water-insoluble anti-cancer drugs 
in order to achieve higher therapeutic concentrations of the drugs in the 
microenvironment of the cancer cells.  
3. Conclusion 
Lipoproteins are complex endogenous aggregates of lipids and proteins that function 
primarily for the transport of water insoluble lipids from their point of origin to their 
respective destinations. Lipoproteins are classified as chylomicrons, very low density 
lipoproteins, low density lipoproteins and high density lipoproteins, based on the relative 
densities of the aggregates on ultracentrifugation.  
Lipoproteins, which are cholesterol-rich particles, have been especially found to play 
significant roles in the pathogenesis of a large number of cancers because rapidly dividing 
cancerous cells generally have high requirements for cholesterol. This is exemplified by the 
increased LDL-requirement associated with a number of cancers including cancers of the 
prostate, colon, adrenal gland etc.  
The efficacy of cancer chemotherapy is often limited by severe deleterious effects induced 
by anticancer drugs, on healthy and cancerous cells because of lack of specificity for the 
cancerous cells. In addition most available anticancer drugs do not perform optimally 
because of limited accessibility to target tissues. The deleterious effects of anticancer drugs 
on healthy organs can be markedly diminished by employing special drug delivery systems 
that specifically target cancer cells, using lipoproteins as carriers. 
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The main advantages of lipoproteins as anti-cancer drug carriers are: (1) lipoproteins are 
spherical particles consisting of a core of apolar lipids surrounded by a phospholipid 
monolayer, in which cholesterol and apoproteins are embedded. Therefore, highly lipophilic 
drugs can be incorporated into the apolar core without affecting lipoprotein receptor 
recognition; (2) lipoproteins are completely bio-degradable, do not trigger immunological 
responses, escape from recognition and elimination by the reticuloendothelial system, and 
have a relatively long half-life in the circulation; (3) lipoproteins can be recognized and 
taken up via specific receptors, and can mediate cellular uptake of the carried drugs ; and (4) 
many cancer cells show a high ability of lipoprotein uptake and therefore high therapeutic 
levels of the conjugated drugs can be rapidly attained at the target site(s).  
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